Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 31 of 35
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
NCT00545948
Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis
NCT00567437
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
NCT00621023
Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer
NCT00564876
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
NCT00565968
Feasibility of Cocooning Immunization Strategy With Influenza Vaccine
NCT00570037
Partnership for Glaucoma
NCT00672048
Phase II Dasatinib Study in Advanced Breast Cancer
NCT00546104
Guided Imagery for Military Sexual Trauma-Related Posttraumatic Stress Disorder (PTSD)
NCT00635635
KAN-DO: A Family-based Intervention to Prevent Childhood Obesity
NCT00563264
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
NCT00597493
Automated Chest Physiotherapy to Improve Outcomes in Neuro
NCT00571623
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
NCT00540254
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
NCT00528788
Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
NCT00734929
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
NCT00612339
Duke Autoimmunity in Pregnancy Registry
NCT00513591
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
NCT00517933
Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II
NCT00734617
Erythropoietin Resistance in Anemia of Chronic Kidney Disease
NCT00526747
A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
NCT00736073
Polycystic Ovarian Syndrome: Impact of Flaxseed Supplementation
NCT00693082
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
NCT00597402
Ketamine In Thoracic Surgery (KITS) Trial
NCT00504725
Risk of Life-threatening Heart Rhythm Disturbances in Siblings
NCT00498524
Engaging Motivation for the Prevention of Weight Regain
NCT01169428
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
NCT00501891
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
NCT00637520
Total Ankle Replacement for Ankle Arthritis
NCT01986244
Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease
NCT00674791
Computerized Cognitive Training for Childhood Cancer Survivors
NCT00629395
CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy
NCT00427193
Coping in African American Prostate Cancer Survivors
NCT00589966
Antidepressant Safety in Kids Study
NCT00395213
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
NCT00479674
Pharmacogenomics of Antidepressant Response in Children and Adolescents
NCT00516932
The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty
NCT00620828
Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer
NCT00509366
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
NCT00476827
Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging
NCT00673283
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
NCT00672243
Pilot Study of Duloxetine in Psychological Resilience
NCT00331799
A Phase I/Expansion Study of Dasatinib
NCT00598091
Alcohol in the Treatment of Obesity
NCT00594074
The Treatment of Insomnia in Patients With HIV Disease
NCT00465972
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
NCT00612430
Metabolic Signatures and Biomarkers in Schizophrenia
NCT00466310
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
NCT00447330
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
NCT00671970
Study of Bimatoprost Gel on Eyelash Growth
NCT01200251
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.